指南与共识乳腺癌支持与姑息治疗

儿童肿瘤学组乳腺癌筛查指南对胸部放疗后霍奇金淋巴瘤生存者的健康获益与成本效益

Health Benefits and Cost-Effectiveness of Children's Oncology Group Breast Cancer Screening Guidelines for Chest-Irradiated Hodgkin Lymphoma Survivors.
指南 / 共识 · J Clin Oncol · 2022-10-20

该研究通过微观模拟评估儿童肿瘤学组指南推荐的乳腺X线摄影和乳腺磁共振成像筛查在女性胸部放疗后儿童霍奇金淋巴瘤生存者中的结局与成本效益,并考察数字乳腺断层合成。结果显示,25-74岁每年MAM在完全依从时具有成本效益;考虑不依从时,仅30-74岁每年MAM(ICER=56,972美元)具有成本效益。

要点

  • 完全依从时,25-74岁每年MAM是唯一具有成本效益的策略(ICER<100,000美元)。
  • 考虑不依从时,仅30-74岁每年MAM(ICER=56,972美元)具有成本效益。
  • 在MAM基础上加做MRI(成本545美元)在两种依从条件下均不具有成本效益。

核心结论

  • 30-74岁每年使用MAM进行乳腺癌筛查在女性胸部放疗后霍奇金淋巴瘤生存者中有效且具有成本效益。
  • 尽管每年辅助MRI在成本为545美元时不具有成本效益,但随着MRI成本降低(如使用简化MRI),可能变得具有成本效益。

研究设计与样本

  • 微观模拟研究,评估25-74岁每年进行MAM、DBT、MRI、MAM+MRI和DBT+MRI筛查的生命年、质量调整生命年、乳腺癌死亡率、医疗费用和假阳性筛查频率。
  • 乳腺癌风险和非乳腺癌死亡率来自儿童癌症生存者研究中女性霍奇金淋巴瘤5年生存者和美国人群。
  • MAM和MRI的检测性能综合自霍奇金淋巴瘤研究,DBT的检测性能来自一般人群。
  • 成本(2017年美元)和效用权重来自医学文献。

主要发现

  • 100%筛查依从时,每年乳腺癌筛查相比不筛查延长生命年0.34-0.46年。
  • 若支付意愿阈值为每获得一个质量调整生命年ICER<100,000美元,25-74岁每年MAM是唯一具有成本效益的策略。
  • 考虑不依从时,仅30-74岁每年MAM(ICER=56,972美元)具有成本效益。
  • 在每年MAM基础上补充MRI(成本545美元)在两种依从条件下均不具有成本效益。
  • 若MRI成本降至300美元,30-74岁每年MAM加MRI可能更具成本效益,尤其在依从性降低条件下(ICER=133,682美元)。

关键数值与推荐

  • 儿童肿瘤学组指南推荐对女性胸部放疗后儿童霍奇金淋巴瘤生存者使用乳腺X线摄影和乳腺磁共振成像进行乳腺癌筛查。
  • 完全依从时,25-74岁每年MAM的ICER<100,000美元。
  • 考虑不依从时,30-74岁每年MAM的ICER=56,972美元。
  • MRI成本为545美元时,在每年MAM基础上加做MRI不具有成本效益。
  • MRI成本降至300美元时,30-74岁每年MAM加MRI在依从性降低条件下的ICER=133,682美元。

临床怎么用

  • 对于女性胸部放疗后霍奇金淋巴瘤生存者,30-74岁每年使用MAM进行乳腺癌筛查是有效且具有成本效益的策略。
  • 每年辅助MRI在成本为545美元时不具有成本效益,但随着MRI成本降低可能变得具有成本效益。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the outcomes and cost-effectiveness of the Children's Oncology Group Guideline recommendation for breast cancer (BC) screening using mammography (MAM) and breast magnetic resonance imaging (MRI) in female chest-irradiated childhood Hodgkin lymphoma (HL) survivors. Digital breast tomosynthesis (DBT), increasingly replacing MAM in practice, was also examined. METHODS: Life years (LYs), quality-adjusted LYs (QALYs), BC mortality, health care costs, and false-positive screen frequencies of undergoing annual MAM, DBT, MRI, MAM + MRI, and DBT + MRI from age 25 to 74 years were estimated by microsimulation. BC risks and non-BC mortality were estimated from female 5-year survivors of HL in the Childhood Cancer Survivor Study and the US population. Test performance of MAM and MRI was synthesized from HL studies, and that of DBT from the general population. Costs (2017 US dollars [USD]) and utility weights were obtained from the medical literature. Incremental cost-effectiveness ratios (ICERs) were calculated. RESULTS: With 100% screening adherence, annual BC screening extended LYs by 0.34-0.46 years over no screening. If the willingness-to-pay threshold to gain a quality-adjusted LY was ICER < $100,000 USD, annual MAM at age 25-74 years was the only cost-effective strategy. When nonadherence was taken into consideration, only annual MAM at age 30-74 years (ICER = $56,972 USD) was cost-effective. Supplementing annual MAM with MRI costing $545 USD was not cost-effective under either adherence condition. If MRI costs were reduced to $300 USD, adding MRI to annual MAM at age 30-74 years could become more cost-effective, particularly in the reduced adherence condition (ICER = $133,682 USD). CONCLUSION: Annual BC screening using MAM at age 30-74 years is effective and cost-effective in female chest-irradiated HL survivors. Although annual adjunct MRI is not cost-effective at $545 USD cost, it could become cost-effective as MRI cost is reduced, a plausible scenario with the emergent use of abbreviated MRI.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Wong FL, Lee JM, Leisenring WM, et al. Health Benefits and Cost-Effectiveness of Children's Oncology Group Breast Cancer Screening Guidelines for Chest-Irradiated Hodgkin Lymphoma Survivors. J Clin Oncol. 2022. PMID: 36265088. doi:10.1200/JCO.22.00574

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。